Interesting:
https://www.fiercepharma.com/special-report/perjeta
This chart is handy:
- perjeta sales estimated to be USD $4.73B in 2022
- “The drug also set a precedent by becoming the first cancer drug approved by the FDA on the back of tumor shrinkage rather than survival data.”
- It’s approved for HER2-positive breast cancer ( about 10-15% of breast cancers )
https://www.grepmed.com/images/3513...agnosis-molecular-incidence-subtypes-invasive
Interesting: https://www.fiercepharma.com/special-report/perjeta...
-
- There are more pages in this discussion • 1 more message in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add RAC (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.61 |
Change
-0.055(3.31%) |
Mkt cap ! $273.4M | |||
| Open | High | Low | Value | Volume |
| $1.66 | $1.68 | $1.61 | $271.5K | 166.3K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 1996 | $1.61 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.68 | 1305 | 2 |
View Market Depth
| Last trade - 16.10pm 26/07/2024 (20 minute delay) ? |
| RAC (ASX) Chart |